Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Journal of Neuropathology and Experimental Neurology
|
January 1, 1994
Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets
E Ulvestad, K Williams, R Matre, et al.
Journal of Neuroimmunology
|
March 1, 1988
Activated suppressor cell function in multiple sclerosis--clinical correlations
J Antel, M Brown, M K Nicholas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 1, 1982
Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis
J Antel, J J Oger, S Jackevicius, et al.
Journal of the American Academy of Dermatology
|
February 1, 1986
Thalidomide and lymphocyte function
I K Aronson, L Weber, D West, et al.
Archives of Dermatology
|
November 1, 1984
Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures
I K Aronson, R Yu, D P West, et al.
Brain : a Journal of Neurology
|
June 3, 2008
Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis
T Kuhlmann, V Miron, Q Cui, et al.
Journal of the Neurological Sciences
|
February 1, 1994
Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG
E Ulvestad, K Williams, C Vedeler, et al.
Journal of the Neurological Sciences
|
August 14, 2009
Gender differences in the histopathology of MS?
T Kuhlmann, T Goldschmidt, J Antel, et al.
Journal of Virology
|
November 24, 2006
Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells
Prabal Banerjee, Rosemary Rochford, J Antel, et al.
Nature Medicine
|
October 4, 2000
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group
L Kappos, G Comi, H Panitch, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Journal of Neuropathology and Experimental Neurology
|
January 1, 1994
Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets
E Ulvestad, K Williams, R Matre, et al.
Journal of Neuroimmunology
|
March 1, 1988
Activated suppressor cell function in multiple sclerosis--clinical correlations
J Antel, M Brown, M K Nicholas, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 1, 1982
Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis
J Antel, J J Oger, S Jackevicius, et al.
Journal of the American Academy of Dermatology
|
February 1, 1986
Thalidomide and lymphocyte function
I K Aronson, L Weber, D West, et al.
Archives of Dermatology
|
November 1, 1984
Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures
I K Aronson, R Yu, D P West, et al.
Brain : a Journal of Neurology
|
June 3, 2008
Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis
T Kuhlmann, V Miron, Q Cui, et al.
Journal of the Neurological Sciences
|
February 1, 1994
Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG
E Ulvestad, K Williams, C Vedeler, et al.
Journal of the Neurological Sciences
|
August 14, 2009
Gender differences in the histopathology of MS?
T Kuhlmann, T Goldschmidt, J Antel, et al.
Journal of Virology
|
November 24, 2006
Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells
Prabal Banerjee, Rosemary Rochford, J Antel, et al.
Nature Medicine
|
October 4, 2000
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group
L Kappos, G Comi, H Panitch, et al.
Page
of 7